NASDAQ:BLPHBellerophon Therapeutics Stock Price, Forecast & News

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BLPH stock has increased by 92.1% and is now trading at $12.08.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bellerophon Therapeutics.

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Bellerophon Therapeutics.

Bellerophon Therapeutics Inc (NASDAQ:BLPH) announced its quarterly earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.21.
View Bellerophon Therapeutics' earnings history.

Shares of Bellerophon Therapeutics reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

4 analysts have issued 1-year target prices for Bellerophon Therapeutics' shares. Their forecasts range from $19.00 to $35.00. On average, they anticipate Bellerophon Therapeutics' share price to reach $28.50 in the next year. This suggests a possible upside of 135.9% from the stock's current price.
View analysts' price targets for Bellerophon Therapeutics.

News stories about BLPH stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bellerophon Therapeutics earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Bellerophon Therapeutics.

Bellerophon Therapeutics saw a increase in short interest in June. As of June 15th, there was short interest totaling 380,700 shares, an increase of 245.5% from the May 31st total of 110,200 shares. Based on an average daily trading volume, of 451,600 shares, the days-to-cover ratio is currently 0.8 days. Approximately 7.1% of the shares of the company are sold short.
View Bellerophon Therapeutics' Short Interest.

Some companies that are related to Bellerophon Therapeutics include DURECT (DRRX), XBiotech (XBIT), BioDelivery Sciences International (BDSI), AC Immune (ACIU), Neoleukin Therapeutics (NLTX), Zafgen (ZFGN), Spectrum Pharmaceuticals (SPPI), Rigel Pharmaceuticals (RIGL), Organogenesis (ORGO), Ocular Therapeutix (OCUL), TherapeuticsMD (TXMD), Avid Bioservices (CDMO), BELLUS Health (BLUSF), ANI Pharmaceuticals (ANIP) and 89bio (ETNB).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Novavax (NVAX), Verastem (VSTM), Gilead Sciences (GILD), SCYNEXIS (SCYX), AVEO Pharmaceuticals (AVEO) and Co-Diagnostics (CODX).

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Bellerophon Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Telemetry Investments L.L.C. (1.32%), DAVENPORT & Co LLC (1.13%), Tocqueville Asset Management L.P. (0.27%), New York State Common Retirement Fund (0.08%) and American International Group Inc. (0.02%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin and Theodore T Wang.
View institutional ownership trends for Bellerophon Therapeutics.

BLPH stock was bought by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, Telemetry Investments L.L.C., Tocqueville Asset Management L.P., New York State Common Retirement Fund, and American International Group Inc.. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin, and Theodore T Wang.
View insider buying and selling activity for Bellerophon Therapeutics.

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BLPH stock can currently be purchased for approximately $12.08.

Bellerophon Therapeutics has a market capitalization of $114.74 million. The biotechnology company earns $-13,270,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe.

The official website for Bellerophon Therapeutics is www.bellerophon.com.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]